Ad is loading...
VISVX
Price
$50.61
Change
+$0.82 (+1.65%)
Updated
Nov 21 closing price
VSMCX
Price
$12.43
Change
+$0.26 (+2.14%)
Updated
Nov 21 closing price
Ad is loading...

VISVX vs VSMCX

Header iconVISVX vs VSMCX Comparison
Open Charts VISVX vs VSMCXBanner chart's image
Vanguard Small Cap Value Index I
Price$50.61
Change+$0.82 (+1.65%)
VolumeN/A
CapitalizationN/A
Invesco Small Cap Value C
Price$12.43
Change+$0.26 (+2.14%)
VolumeN/A
CapitalizationN/A
VISVX vs VSMCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
VISVX vs. VSMCX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is VISVX is a Buy and VSMCX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. VSMCX (6.34B). VISVX pays higher dividends than VSMCX: VISVX (1.90) vs VSMCX (0.40). VISVX was incepted earlier than VSMCX: VISVX (27 years) vs VSMCX (25 years). VSMCX is a more actively managed with annual turnover of: 51.00 vs. VISVX (16.00). VSMCX has a lower initial minimum investment than VISVX: VSMCX (1000) vs VISVX (3000). VSMCX (31.30) and VISVX (30.04) have marching annual gain over last year. VISVX return over 5 years is better than : 62.14 vs. VSMCX (41.75).
VISVXVSMCXVISVX / VSMCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence27 years25 years-
Gain YTD17.71229.61460%
Front LoadN/AN/A-
Min. Initial Investment30001000300%
Min. Initial Investment IRAN/AN/A-
Net Assets57.6B6.34B908%
Annual Yield % from dividends1.900.40470%
Returns for 1 year30.0431.3096%
Returns for 3 years16.92-6.95-244%
Returns for 5 years62.1441.75149%
Returns for 10 years109.83-33.79-325%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EFXT9.240.20
+2.21%
Enerflex Ltd
RVSN0.440.01
+1.60%
Rail Vision Ltd
CAG27.170.05
+0.18%
Conagra Brands
FULC2.97-0.02
-0.67%
Fulcrum Therapeutics
KYMR43.51-0.54
-1.23%
Kymera Therapeutics